State Street Corp Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM)

State Street Corp lowered its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 7.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,187,466 shares of the company's stock after selling 176,768 shares during the quarter. State Street Corp owned 3.64% of Immunome worth $31,981,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IMNM. Wealth Enhancement Advisory Services LLC raised its holdings in Immunome by 279.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 41,570 shares of the company's stock worth $503,000 after purchasing an additional 30,617 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in Immunome by 18.2% in the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company's stock worth $317,000 after purchasing an additional 4,035 shares during the period. Bank of New York Mellon Corp bought a new position in Immunome in the second quarter worth $1,816,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Immunome in the second quarter worth $97,000. Finally, Rhumbline Advisers purchased a new position in Immunome during the second quarter valued at $813,000. Institutional investors own 44.58% of the company's stock.

Immunome Price Performance

Immunome stock traded down $0.11 during midday trading on Friday, reaching $10.97. 1,453,565 shares of the company traded hands, compared to its average volume of 782,940. Immunome, Inc. has a 12 month low of $8.15 and a 12 month high of $30.96. The business has a 50 day moving average of $12.14 and a two-hundred day moving average of $13.34. The firm has a market capitalization of $684.71 million, a price-to-earnings ratio of -1.35 and a beta of 1.83.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stephens started coverage on shares of Immunome in a research report on Friday, November 8th. They issued an "overweight" rating and a $30.00 target price on the stock. Piper Sandler cut their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Finally, Wedbush reaffirmed an "outperform" rating and set a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $28.83.

Insider Activity

In other Immunome news, insider Robert Lechleider acquired 15,805 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the transaction, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were bought at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 102,862 shares of company stock valued at $978,045 in the last ninety days. 8.60% of the stock is currently owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.